| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4026005 | Ophthalmology | 2015 | 10 Pages |
Abstract
Pazopanib was well tolerated. Daily pazopanib eye drops in neovascular AMD subjects did not result in therapeutic benefit beyond that obtained with ranibizumab alone.
Keywords
CNVIVTAMDQIDPEDCFHSAEBCVAChoroidal neovascularizationfluorescein angiographyOctbest-corrected visual acuityOptical coherence tomographyComplement factor HPigment epithelial detachmentVisual acuityintravitrealTIDage-related macular degenerationadverse eventSerious adverse eventpharmacokineticconfidence intervalVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Karl G. MD, Pravin U. MD, Amy J. Pierce, Michael A. PhD, Deborah S. MD, Ronald P. MD, John I. MD, MPH, Chun-Fang PhD, Mohammad PhD, Trupti PhD,